Evotec SE (EVO) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Evotec SE (EVO) Healthcare & Pipeline Overview

Evotec SE, based in Hamburg, Germany, partners with pharmaceutical and biotechnology companies, offering drug discovery and development services across diverse therapeutic areas. With a broad portfolio of collaboration agreements, Evotec focuses on advancing pharmaceutical products in areas like diabetes, oncology, and infectious diseases, positioning itself as a key player in the global drug development ecosystem.

What Is the Investment Thesis for EVO?

Evotec SE presents a compelling, albeit risky, investment case. The company's role as a drug discovery and development partner positions it to capitalize on the increasing demand for outsourced research and development in the pharmaceutical industry. Evotec's extensive collaboration network with major pharmaceutical companies provides a steady stream of revenue and validation of its scientific capabilities. However, the company's negative profit margin of -26.0% raises concerns about its profitability and operational efficiency. Key catalysts include the advancement of its drug development pipeline and the signing of new collaboration agreements. The company's beta of 1.24 indicates higher volatility compared to the market. Investors should closely monitor Evotec's ability to improve its profitability and manage its operational costs. The company's success hinges on its ability to translate its research and development efforts into commercially viable products and maintain strong relationships with its partners.

Based on FMP financials and quantitative analysis

EVO Key Highlights

Evotec SE operates as a drug discovery and development partner for the pharmaceutical and biotechnology industry, offering services across a broad range of therapeutic areas.

• The company has established collaboration agreements with major pharmaceutical companies, including Bayer AG, Lilly, and Pfizer Inc., providing a diversified revenue stream.
• Evotec's market capitalization stands at $629M, reflecting its position as a significant player in the drug development sector.
• The company's gross margin is 11.5%, indicating the profitability of its core services after accounting for the cost of goods sold.
• Evotec employs 4766 individuals, highlighting the scale of its operations and research capabilities.

Who Are EVO's Competitors?

EVO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are EVO's Key Strengths?

Strong collaboration network with major pharmaceutical companies.

• Diverse therapeutic focus across multiple disease areas.
• Integrated drug discovery platform offering end-to-end solutions.
• Experienced management team with a proven track record.

What Are EVO's Weaknesses?

Negative profit margin indicating profitability challenges.

• High reliance on collaboration agreements for revenue generation.
• Exposure to regulatory risks and clinical trial failures.
• Competition from other contract research organizations (CROs).

What Could Drive EVO Stock Higher?

Advancement of drug candidates in Evotec's pipeline through clinical trials.

• Potential new collaboration agreements with pharmaceutical and biotechnology companies.
• Expansion of Evotec's research and development capabilities in key therapeutic areas.
• Regulatory approvals for new drugs developed through Evotec's partnerships.

What Are the Key Risks for EVO?

Financial-distress signal — its Altman Z-Score of -0.09 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-24.5%) — the business is not currently generating profit on shareholder capital.
• Inconsistent delivery — missed Wall Street EPS estimates in 7 of the last 8 reported quarters.
• Clinical trial failures and setbacks in drug development programs.
• Intense competition from other contract research organizations (CROs).
• Regulatory changes and stricter approval requirements.
• Economic downturns impacting pharmaceutical R&D spending.
• Currency fluctuations affecting the value of Evotec's ADR.

What Are the Growth Opportunities for EVO?

• Expansion into New Therapeutic Areas: Evotec has the opportunity to expand its research and development efforts into new therapeutic areas, such as gene therapy and precision medicine. These emerging fields are experiencing rapid growth and offer significant potential for new drug discoveries. The global gene therapy market is projected to reach $25 billion by 2028, presenting a substantial opportunity for Evotec to diversify its portfolio and attract new partnerships. Timeline: Ongoing.
• Strengthening Collaboration Agreements: Evotec can further strengthen its existing collaboration agreements with pharmaceutical companies and forge new partnerships with emerging biotech firms. These collaborations provide access to funding, expertise, and market access, accelerating the development and commercialization of new drugs. The increasing trend of outsourcing in the pharmaceutical industry creates a favorable environment for Evotec to expand its collaboration network. Timeline: Ongoing.
• Geographic Expansion: Evotec has the potential to expand its geographic presence into new markets, particularly in Asia and emerging economies. These regions are experiencing rapid growth in healthcare spending and offer significant opportunities for Evotec to establish new partnerships and expand its customer base. The increasing demand for innovative drugs in these markets creates a favorable environment for Evotec's expansion. Timeline: Ongoing.
• Leveraging Artificial Intelligence and Machine Learning: Evotec can leverage artificial intelligence (AI) and machine learning (ML) technologies to accelerate drug discovery and development. AI and ML can be used to identify promising drug candidates, optimize clinical trial design, and personalize treatment approaches. The application of AI and ML in drug discovery is expected to significantly reduce the time and cost of developing new drugs. Timeline: Ongoing.
• Developing Proprietary Drug Candidates: Evotec has the opportunity to develop its own proprietary drug candidates, in addition to its partnered programs. This would allow the company to capture a greater share of the value created from its research and development efforts. Developing proprietary drug candidates requires significant investment and carries higher risk, but it also offers the potential for higher returns. Timeline: Ongoing.

What Are EVO's Competitive Advantages?

• Extensive Collaboration Network: Evotec's established relationships with major pharmaceutical companies provide a competitive advantage.
• Diverse Therapeutic Focus: The company's presence across multiple therapeutic areas reduces its reliance on any single market.
• Integrated Drug Discovery Platform: Evotec's comprehensive suite of services, from target identification to preclinical testing, offers a one-stop solution for its partners.
• Proprietary Technologies: Evotec's utilization of advanced technologies and platforms accelerates the drug discovery process.

What Does EVO Do?

Evotec SE, founded in 1993 and headquartered in Hamburg, Germany, operates as a drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. Originally named Evotec AG, the company rebranded to Evotec SE in April 2019. Evotec's core business revolves around developing pharmaceutical products across a wide array of therapeutic areas, including diabetes and its complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. The company leverages its research and development capabilities to form strategic collaboration agreements with major players in the pharmaceutical sector, such as Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. These collaborations are crucial for Evotec's growth, providing both funding and expertise to advance its drug development pipeline. Evotec's geographic reach is global, serving clients and partners across the world. The company competes with other contract research organizations (CROs) and drug development firms, differentiating itself through its diverse therapeutic focus and extensive collaboration network.

What Products and Services Does EVO Offer?

• Evotec SE partners with pharmaceutical and biotechnology companies to discover and develop new drugs.
• The company provides a range of services, including target identification, drug design, and preclinical testing.
• Evotec develops pharmaceutical products across various therapeutic areas, such as diabetes, oncology, and infectious diseases.
• The company collaborates with major pharmaceutical companies through strategic agreements.
• Evotec leverages its research and development capabilities to advance its drug development pipeline.
• Evotec offers integrated drug discovery solutions, from target validation to IND-enabling studies.
• The company utilizes advanced technologies and platforms to accelerate the drug discovery process.

How Does EVO Make Money?

• Evotec generates revenue through collaboration agreements with pharmaceutical and biotechnology companies.
• The company receives upfront payments, research funding, and milestone payments as part of these agreements.
• Evotec may also receive royalties on the sales of drugs developed through its partnerships.

What Industry Does EVO Operate In?

Evotec SE operates within the drug manufacturing industry, specifically in the specialty and generic drug segment. This industry is characterized by intense competition, rapid technological advancements, and stringent regulatory requirements. Evotec's position as a drug discovery and development partner allows it to capitalize on the trend of pharmaceutical companies outsourcing their research and development activities. Competitors like SYRE: Spyre Therapeutics, Inc. also vie for market share in this dynamic landscape.

Who Are EVO's Key Customers?

• Pharmaceutical companies seeking to outsource their drug discovery and development activities.
• Biotechnology companies looking for partners to advance their drug candidates.
• Academic institutions and research organizations collaborating on drug discovery projects.

Company Profile

Evotec SE operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Hamburg, DE. The company is led by CEO Christian Wojczewski. EVO has traded publicly since 2004.

Evotec SE Financial Trajectory

Evotec SE (EVO) reported $169.2M in revenue for Q2 FY2026, a decline of 8.4% compared to the prior quarter. The company recorded a net loss of $55.0M, with diluted EPS of $-0.15. Revenue has contracted over three consecutive quarters, which investors in this small-cap Healthcare stock should monitor closely. Across the four most recent quarters, EVO averaged $-0.16 in diluted EPS.

How Evotec SE Is Valued

Evotec SE carries a market capitalization of $629M, placing it in the small-cap category. Analyst price targets span from $2.00 to $4.00, with a consensus of $3.00. At the current price of $1.77, that implies approximately 69% upside potential. Relative to its peer group, EVO's quantitative score of 20/100 is below the peer average of 63/100.

Return on equity for Evotec SE stands at -24.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -11.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -4.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.68 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -21.3%, the inverse of the P/E and a quick read on earnings relative to price.

Evotec SE's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -0.09 places it in the distress zone, a signal of elevated financial risk.

Evotec SE has missed Wall Street's EPS estimate in 7 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 174.5% below estimates on average.

The most recent 6 insider filings for Evotec SE break down as 2 sales and 4 purchases. On net that is roughly 500K shares acquired (about $1.3M) — insiders putting money in tends to read as conviction.

EVO Financials

EVO Latest News

EVO Analyst Consensus

EVO MoonshotScore

EVO Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources